Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), JNK2 inhibitors(c-Jun N-terminal kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | EG | 01 Apr 2024 |